AG Telmisartan-HCT Tablet: Out of specification (Assay)
Brand(s)
Last updated
Summary
Product
AG Telmisartan-HCT Tablet
Issue
Health products - Product quality
What to do
Consult your health care professional if you have any health concerns.
Affected products
Brand |
Product Name |
Market Authorization |
Dosage Form |
Strength |
Lot numbers |
|---|---|---|---|---|---|
Angita |
AG Telmisartan-HCT Tablet |
DIN 02484579 |
Tablet |
Telmisartan 80 mg |
EG23AGL002 |
Issue
The assay in telmisartan is out of specification in the affected lots.
What you should do
- Verify if your product is affected.
- Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
- Contact the recalling firm if you have any questions about the recall.
- Report any health product related side effects to Health Canada.
- Report any other health product safety complaints to Health Canada.
Additional information
Background
Depth of recall: Retailers
Details
Original published date:
Alert / recall type
Health product recall
Category
Health products - Drugs
Companies
Recalling firm:
JAMP Pharma Corporation.
1310 Nobel,
Boucherville, QC, J4B 5H3
Market Authorization Holder:
ANGITA PHARMA INC.
1310 Rue Nobel,
Boucherville, QC J4B 5H3
Published by
Health Canada
Audience
General public
Healthcare
Industry
Recall class
Type II
Identification number
RA-76036
Get notified
Receive notifications for new and updated recalls and alerts by category.